Catalyst Biosciences, Inc. (CBIO)
| Previous close | 0.1900 |
| Open | 0.2000 |
| Bid | 0.1906 x 40700 |
| Ask | 0.1999 x 1200 |
| Day's range | 0.1900 - 0.2000 |
| 52-week range | 0.1900 - 2.0900 |
| Volume | |
| Avg. volume | 1,590,441 |
| Market cap | 7.514M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9320 |
| Earnings date | 29 Mar 2023 - 03 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Jan 2023 |
| 1y target est | 16.00 |
- GlobeNewswire
Catalyst Biosciences Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)
- GlobeNewswire
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21
- Simply Wall St.
Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)
Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...
